Patent Law Weblog
recent posts
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
- United States Files Statement of Interest in Patent Infringement Proceedings
about
Month: June 2012
-
By James DeGiulio — The Leahy-Smith America Invents Act changed the law on prior user rights ("PUR") in the United States, providing protection for inventors' trade secrets and protection against infringement liability from a later granted patent. This change in the law brings the U.S. closer to harmonization with many other countries with these rights,…
-
By Donald Zuhn — Last week, a group of 23 industrial, environmental, food, and agricultural biotechnology companies sent a letter to Attorney General Eric H. Holder, Jr. and Solicitor General Donald Verrilli, Jr., expressing their concerns over Association for Molecular Pathology v. Myriad, which was remanded back to the Federal Circuit in light of Mayo Collaborative…
-
By Kevin E. Noonan — Janet Gongola, Patent Reform Coordinator at the U.S. Patent and Trademark Office, and manager of all aspects of the agency's implementation of the Leahy-Smith America Invents Act has informed Patent Docs that the Office's report on "second opinion" genetic diagnostic testing has been delayed past its nominal deadline date of…
-
By Kwame Mensah — A free-flowing panel discussing the potential impact of Mayo Collaborative Services v. Prometheus Laboratories, Inc. on the future of personalized medicine and diagnostic method patents in the United States, and the possible slippery slope that could be encountered if its holding is stretched to the claims in the Myriad case as…
-
By Kevin E. Noonan — The deadline for filing "supplemental briefs" in Association for Molecular Pathology v. U.S. Patent and Trademark Office ("the Myriad case") was Friday, and in addition to Appellants Myriad (Supplemental Brief for Appellant (Myriad)) and Appellees represented by the ACLU and Public Patent Foundation (here), more than a dozen amicus curiae…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Janssen Products, L.P. et al. v. Hetero Drugs, Ltd., Unit III et al.2:12-cv-03570; filed June 13, 2012 in the District Court of New Jersey • Plaintiffs: Janssen Products, L.P.; Janssen R&D Ireland; G.D. Searle, LLC•…
-
June 18-21, 2012 – BIO International Convention (Biotechnology Industry Organization) – Boston, MA June 19, 2012 – Post-Grant Proceedings after the AIA (Law Seminars International) – 3:00 – 4:00 pm (Eastern) June 20-21, 2012 – International Forum on Pharma Patent Lifecycles*** (C5) – London, England July 23-24, 2012 – Patent Cooperation Treaty Seminar (American Intellectual…
-
The Biotechnology Industry Organization (BIO) will be holding its annual BIO International Convention next week in Boston, MA. Founded in 1993, BIO is a nonprofit association seeking supportive biotechnology policies on behalf of more than 1,100 biotechnology companies, state and international affiliates, and related organizations, as well as providing business development services for many emerging…
-
Law Seminars International (LSI) will be offering a one-hour telebriefing on the "Post-Grant Proceedings after the AIA" on June 19, 2012 from 3:00 – 4:00 pm (Eastern). Wab P. Kadaba of Kilpatrick Townsend & Stockton LLP will moderate a panel including Wilson White, Associate Litigation Counsel of Google Inc., who will provide an in-house perspective…
-
By Kevin E. Noonan — Last year, the Australian Senate rejected a call for banning patents on human genes in Australia. This result came after almost a decade of debate, resulting in several Reports (including the 2011 ACIP Report on Patentable Subject Matter, the Senate Gene Patents Report, issued November 24, 2010, and the 2004…
Patent Docs 